📚 New to this topic? Read our full guide: Indian Economy Explained.

Biopharma Shakti Scheme To Roll Out In 3 Months With Focus On Faster Drug Approvals

India has a big new plan called the Biopharma Shakti scheme. A scheme is just a government plan or program. It will start in about three months. This news came from Manoj Joshi. He is a top officer in the Department of Pharmaceuticals (the part of the government that looks after medicines).

The plan wants to make India a world leader in modern medicines. It also promises to approve new medicines faster. “Approve” means the government says a medicine is safe and people are allowed to sell it. The plan will also help new small companies. This could change India’s medicine business in a big way.

The plan is very large. The government has kept aside ₹10,000 crore for it. That money will be used over five years. (One crore is ten million, so this is a huge sum.) The goal is to build a strong, India-made system to make special medicines. We explain those medicines below in easy words.

What Is Biopharma Shakti In Simple Words?

Biopharma Shakti is a government plan to grow India’s modern medicine field. It is mainly about two kinds of medicine: biologics and biosimilars.

A biologic is a medicine made from living cells, not from chemicals. It is used to treat illnesses like cancer and diabetes (a disease where the body cannot control sugar in the blood). A biosimilar is a cheaper, near-copy of a biologic. It is made after the time period when only one company is allowed to sell the original medicine ends.

These medicines cost a lot and are hard to make. India wants to make more of them inside the country.

Manoj Joshi is the Secretary (a senior officer) of the Department of Pharmaceuticals. This department is part of the Ministry of Chemicals and Fertilizers. He said the plan will start in about three months. He wants India to invent more, find new medicines faster, help new medicine companies, and make the supply of medicines more steady.

Faster Drug Approvals Are A Big Promise

One of the biggest goals is to approve new medicines faster. Right now, getting a new medicine cleared in India can take a long time. The plan wants to make the CDSCO stronger. The CDSCO is India’s main drug regulator. A regulator is the body that checks if a medicine is safe before anyone is allowed to sell it.

To help with this, the government will set up a special team of experts. It is called the Scientific Review Cadre. This team will check new medicine requests. The aim is to give quick approvals that other countries also trust. That way, Indian companies can launch medicines sooner and sell them in other countries too.

Big Money For Startups And Small Firms

The plan gives real money to startups and small companies. A startup is a brand-new company that is just getting started. This money helps with the high cost of building factories that make biologics.

For smaller projects worth up to ₹9 crore, a startup or MSME can get up to ₹5 crore in help. MSME means micro, small and medium enterprise — in simple words, a small or mid-sized business. For bigger projects worth up to ₹285 crore, the most help a company can get is ₹100 crore.

Key fact	Figure (as reported)
Total scheme outlay	₹10,000 crore
Scheme duration	5 years
Expected rollout	about 3 months
Help for projects up to ₹9 crore	up to ₹5 crore
Help for projects up to ₹285 crore	up to ₹100 crore
Long-term goal	100 biologics by 2047

The Long-Term Vision

The plan looks far into the future. India wants to launch 100 biologics by the year 2047. That year marks 100 years since India became free. Before starting, the Department of Pharmaceuticals talked with many people. It spoke with other government bodies, business leaders, startups, and firms that do research and make medicines for others. The plan will start once all the approvals are done. This includes a yes from the Expenditure Finance Committee (a group that checks big government spending) and from the Cabinet (the top group of ministers who run the country).

FAQ

When will Biopharma Shakti roll out?

Pharma Secretary Manoj Joshi said it should start in about three months. First it needs a final yes from the Expenditure Finance Committee and the Cabinet (the top group of ministers).

How much money is in the scheme?

The plan has ₹10,000 crore in total. That money will be spent over five years. It will be used to build India’s system for making biologics and biosimilars (modern medicines and their cheaper copies).

How will it help startups?

Startups and MSMEs (small and mid-sized businesses) can get up to ₹5 crore for projects up to ₹9 crore. They can get up to ₹100 crore for projects up to ₹285 crore. This cuts the high cost of getting started.

Why It Matters (Especially For India And Founders)

India is already called the “pharmacy of the world.” This is because it makes many cheap generic medicines. A generic medicine is a copy of a well-known medicine that costs less. But biologics are the medicines of the future. They cost a lot and are hard to make. This plan helps India catch up.

For founders in biotech (people who start companies that use biology to make medicines), the plan helps a lot. The money support and faster approvals remove two big problems: cash and time.

This fits India’s bigger goal to lead in high-tech and high-value work. It is much like the country’s wider push in AI and new ideas. More India-made biologics also mean cheaper life-saving medicines for Indian patients. It also makes the country’s medicine supply stronger.

The bottom line: Biopharma Shakti is a ₹10,000 crore bet on India’s medicine future. It promises faster approvals, big help for startups, and a goal of 100 biologics by 2047. The three-month start could change India’s medicine map.

Sources: Financial Express and Press Information Bureau.